CytomX Therapeutics, Inc. - 8-K Filing
CytomX Therapeutics and Regeneron Pharmaceuticals amended their collaboration agreement to extend the program selection period and add up to eight new programs, with Regeneron already nominating two for $37 million in payments. The total potential value of all nominations, milestones, and royalties under the deal remains approximately $4 billion. (Items: 1.01 Entry into a Material Definitive Agreement)
Tickers: $CTMX